End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 11 | Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating | MT |
Jul. 10 | Perrigo Divests HRA Pharma Rare Diseases Business to Esteve Healthcare | MT |
Financials (USD)
Sales 2024 * | 4.62B | Sales 2025 * | 4.83B | Capitalization | 3.75B |
---|---|---|---|---|---|
Net income 2024 * | -74M | Net income 2025 * | 103M | EV / Sales 2024 * | 1.51 x |
Net Debt 2024 * | 3.21B | Net Debt 2025 * | 3.01B | EV / Sales 2025 * | 1.4 x |
P/E ratio 2024 * |
-19
x | P/E ratio 2025 * |
172
x | Employees | - |
Yield 2024 * |
4.01% | Yield 2025 * |
4.27% | Free-Float | 99.66% |
Latest transcript on Perrigo Company
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 23-06-29 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 22-05-15 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 20-12-14 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 17-02-05 |
Bradley Alford
BRD | Director/Board Member | 67 | 17-02-05 |
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |